| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.005 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.086 | 0.005 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.005 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.007 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.008 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.009 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.13 | 0.009 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | -0.097 | 0.009 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |